188 related articles for article (PubMed ID: 38155946)
21. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas.
Araujo-Castro M; Mínguez Ojeda C; García Centeno R; López-García MC; Lamas C; Hanzu FA; Mora M; Del Castillo Tous M; Rodríguez de Vera Gómez P; Parra Ramírez P; Alvarez-Escola C; Blanco Carrera C; Barahona San Millán R; Recasens M; Valdés N; Gracia Gimeno P; de Miguel Novoa P; Vicente A; Manjón L; García Sanz I; Michalopoulou T; Calatayud M
Endocr Relat Cancer; 2022 Dec; 29(12):645-655. PubMed ID: 36069783
[TBL] [Abstract][Full Text] [Related]
22. Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.
Sue M; Martucci V; Frey F; Lenders JM; Timmers HJ; Peczkowska M; Prejbisz A; Swantje B; Bornstein SR; Arlt W; Fassnacht M; Beuschlein F; Robledo M; Pacak K; Eisenhofer G
Eur J Endocrinol; 2015 Feb; 172(2):89-95. PubMed ID: 25371406
[TBL] [Abstract][Full Text] [Related]
23. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
24. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
25. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
26. Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas.
Petenuci J; Guimaraes AG; Fagundes GFC; Benedetti AFF; Afonso ACF; Pereira MAA; Zerbini MCN; Siqueira S; Yamauchi F; Soares SC; Srougi V; Tanno FY; Chambo JL; Lopes RI; Denes FT; Hoff AO; Latronico AC; Mendonca BB; Fragoso MCBV; Almeida MQ
Clin Endocrinol (Oxf); 2021 Jul; 95(1):117-124. PubMed ID: 33745191
[TBL] [Abstract][Full Text] [Related]
27. Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.
Deljou A; Kohlenberg JD; Weingarten TN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
BMC Anesthesiol; 2018 Nov; 18(1):158. PubMed ID: 30400849
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
van Berkel A; Lenders JW; Timmers HJ
Eur J Endocrinol; 2014 Mar; 170(3):R109-19. PubMed ID: 24347425
[TBL] [Abstract][Full Text] [Related]
29. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
Pamporaki C; Berends AMA; Filippatos A; Prodanov T; Meuter L; Prejbisz A; Beuschlein F; Fassnacht M; Timmers HJLM; Nölting S; Abhyankar K; Constantinescu G; Kunath C; de Haas RJ; Wang K; Remde H; Bornstein SR; Januszewicz A; Robledo M; Lenders JWM; Kerstens MN; Pacak K; Eisenhofer G
Lancet Digit Health; 2023 Sep; 5(9):e551-e559. PubMed ID: 37474439
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas and sympathetic paragangliomas.
Araujo-Castro M; García Sanz I; Mínguez Ojeda C; Hanzu F; Mora M; Vicente A; Blanco Carrera C; Miguel Novoa P; López García MDC; Lamas C; Manjón-Miguélez L; Del Castillo Tous M; Rodríguez de Vera P; Barahona San Millán R; Recasens M; Fernández-Ladreda MT; Valdés N; Gracia Gimeno P; Robles Lazaro C; Michalopoulou T; Álvarez Escolá C; García Centeno R; Calatayud M
J Hypertens; 2024 Feb; 42(2):252-259. PubMed ID: 37851004
[TBL] [Abstract][Full Text] [Related]
31. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
32. Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
Kuo MJM; Nazari MA; Jha A; Pacak K
Front Endocrinol (Lausanne); 2022; 13():936178. PubMed ID: 35903274
[TBL] [Abstract][Full Text] [Related]
33. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
34. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
35. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
[TBL] [Abstract][Full Text] [Related]
36. Somatic IDH1 Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas.
Li M; He Y; Pang Y; Zhang J; Feng Y; He Y; Xu X; Wei Y; Zhong D; Deng W; Wang L; Yan B; Jiang Y; Xu N; Cai H; Wen Y; Ning J; Liu Y; Gao X; Shan Z; Liu L; Teng X; Richter S; Jiang J
J Clin Endocrinol Metab; 2023 Apr; 108(5):1215-1223. PubMed ID: 36355572
[TBL] [Abstract][Full Text] [Related]
37. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
38. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
Xu S; Pan Y; Zhou J; Ju H; Zhang Y
Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455
[TBL] [Abstract][Full Text] [Related]
39. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
40. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.
Dahia PLM; Clifton-Bligh R; Gimenez-Roqueplo AP; Robledo M; Jimenez C
Endocr Relat Cancer; 2020 Aug; 27(8):T41-T52. PubMed ID: 32069214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
